› 7eu7

Electron Microscopy
3.5Å resolution

Structure of the human GluN1-GluN2A NMDA receptor in complex with S-ketamine, glycine and glutamate

Released:
DOI: 10.2210/pdb7eu7/pdb
PDB entry 7eu7 coloured by chain, front view.
PDB entry 7eu7 coloured by chain, side view.
PDB entry 7eu7 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structural basis of ketamine action on human NMDA receptors.
Zhang Y, Ye F, Zhang T, Lv S, Zhou L, Du D, Lin H, Guo F, Luo C, Zhu S
Nature 596 301-305 (2021)
PMID: 34321660
Related structures: EMD-31308

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero tetramer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-170224 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Glutamate receptor ionotropic, NMDA 1 Chains: A, C
Molecule details ›
Chains: A, C
Length: 847 amino acids
Theoretical weight: 95.24 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
UniProt:
  • Canonical: Q05586 (Residues: 1-847; Coverage: 90%)
Gene names: GRIN1, NMDAR1
Sequence domains:
Glutamate receptor ionotropic, NMDA 2A Chains: B, D
Molecule details ›
Chains: B, D
Length: 841 amino acids
Theoretical weight: 94.14 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
UniProt:
  • Canonical: Q12879 (Residues: 1-841; Coverage: 57%)
Gene names: GRIN2A, NMDAR2A
Sequence domains:

Ligands and Environments

4 bound ligands:
Ligand NAG 24 x NAG
Ligand GLY 2 x GLY
Ligand GLU 2 x GLU
Ligand JC9 1 x JC9
No modified residues

Experiments and Validation Details

Entry percentile scores
Resolution: 3.5Å
Relevant EMDB volumes: EMD-31308
Expression system: Homo sapiens

Quick links

Citations

11 review citations

Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.
Xu et al. (2021)
10 more

6 mentions without citation

GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases.
Ladagu et al. (2023)
5 more